Dr. Serhat Gümrükcü
Dr. Serhat Gümrükcü has been at the forefront of cell, gene and immunotherapy for more than a decade. After his medical training at Dokuz Eylul University (2004) and Istanbul Marmara University (2006), he continued his clinical training and practice in different centers around Europe including University of Edinburgh United Kingdom, Pierre & Marie Curie University Saint Antoine Teaching Hospital, France and Institute of Bioregulation St Petersburg, Russia.
His interest in other fields of science, like physics, has led him to pursue creating cross-disciplinary solutions to complex human diseases as a researcher of his own clinical work and as a consulting diagnostician and clinician for heads of states, prominent families and world leaders. Besides his professional work in the field, he has spent significant amount of time providing medical care to underserved communities in Africa, Asia and the Middle East. Dr. Gümrükçü’s innovative research has focused on cancer immunotherapy, stem cell and transplant biology, and regenerative medicine. His main objective is to develop better stem cell transplant, and cell and gene therapy treatments for patients with cancer, rare genetic disorders, and infectious diseases.
Based on his unique research training, Dr. Gümrükcü has become a prolific inventor, submitting various patents including for several approaches to cure HIV/AIDS, Hepatitis B, major solid tumors, rare but deadly diseases, and for a novel vaccine for HIV among many others.
Dr. Gümrükcü has licensed all intellectual property related to HIV and several solid tumors to Enochian Biosciences, where he serves as Senior Scientific Advisor. He is the director of Seraph Research Institute, a non-profit organization where he also runs his research lab at the cutting edge of cell, gene and immunotherapy.
Dr. Gümrükcü is a member of American Society of Clinical Oncology (ASCO), International AIDS Society (IAS), HIV Medicine Association (HIVMA), and American Society of Gene & Cell Therapy (ASGCT) where he was appointed to serve on the Cancer Cell & Gene Therapy Committee and Infectious Diseases and Vaccines Committee in recognition of his “leadership in the field”.